Jane Street
CCCC icon

Jane Street’s C4 Therapeutics CCCC Stock Holding History

Jane Street’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$112K Buy
+33,600
New +$125K ﹤0.01% 10518
2026
Q2 		– Sell
-13,100
Closed -$34.5K – 11661
2026
Q1 		$34.5K Buy
+13,100
New +$30.8K ﹤0.01% 11080
2024
Q1 		– Sell
-54,700
Closed -$309K – 9247
2023
Q4 		$309K Buy
+54,700
New +$125K ﹤0.01% 7556

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Jane Street's CCCC Position: Q3 2026 in Review

Jane Street reduced its C4 Therapeutics (CCCC) stake by 18% in Q3 2026, selling an estimated $202K and leaving 248,476 shares worth $827K. The position accounts for ﹤0.01% of the portfolio, ranked #6868.

Jane Street first reported a position in CCCC in Q1 2021 and has held it in 16 quarters since. The position peaked at $3.28M in Q1 2026. 91 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Jane Street held 248,476 shares of C4 Therapeutics worth $827K as of Q3 2026.
  • Jane Street sold 54,274 C4 Therapeutics shares in Q3 2026, an estimated $202K.
  • C4 Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #6868 holding.
  • Jane Street first reported a position in C4 Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Jane Street's C4 Therapeutics position peaked at $3.28M in Q1 2026.
  • 91 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.